Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, introduced Ms. Muneerah Kanji, MBA, CPA, CA, Crescita's Corporate Controller, as Interim Chief Financial Officer replacing Mr. Mario Laflamme who has resigned for health-related family reasons. Crescita has commenced a formal search process for a new Chief Financial Officer.
"Ms. Kanji brings a wealth of global financial and operations experience to Crescita and we look forward to her input in her new role," said Dan Chicoine, Crescita's Executive Chairman and Interim Chief Executive Officer. "We appreciate Mr. Laflamme's efforts and contributions to the Company and wish him well."
Prior to joining Crescita, Ms. Kanji was the Vice President, Finance for Remedy Holdings Inc., and has held senior roles in Finance in the healthcare sector at MDS Inc. and Baxter Canada with responsibilities for planning, reporting, information technology, human resources, tax, treasury and mergers and acquisitions. Ms. Kanji is a Chartered Professional Accountant and holds a Master of Business Administration from Queen's University.
Theodore Stanley, MD has resigned from the Crescita Board of Directors and Corporate Governance, Compensation and Nominating Committee. Dr. Stanley is a co-founder of ZARS Pharma Inc. (ZARS) and joined the Board of Directors of Nuvo Research Inc. (Nuvo) (Crescita was spun out from Nuvo in March 2016) when ZARS was acquired by Nuvo in May 2011.
"We would like to thank Dr. Stanley for his dedicated service to Nuvo and most recently to Crescita," said Mr. Chicoine. "We wish him continued success in his future endeavours."Next Story